Benitec Biopharma
BNTC
25 hedge funds and large institutions have $5.92M invested in Benitec Biopharma in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
2,890% more capital inflows, than outflows
Capital inflows: $11.1M | Capital outflows: $372K
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
45.28% more ownership
Funds ownership: 16.39% → 61.67% (+45%)
19% more funds holding
Funds holding: 21 → 25 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$7.47M |
| 2 |
Armistice Capital
New York
|
+$1.16M |
| 3 |
CVI Holdings
Wilmington,
Delaware
|
+$963K |
| 4 |
Empery Asset Management
New York
|
+$596K |
| 5 |
ACM
Altium Capital Management
New York
|
+$492K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$158K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$62K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$58K |
| 4 |
Virtu Financial
New York
|
-$55K |
| 5 |
Two Sigma Securities
New York
|
-$28K |
BNTC Hedge Fund Activity: Q3 2022 in Review
25 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2022, worth a combined $5.92M — up 281% from $1.55M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BNTC positions and 6 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $7.47M. The largest seller was Barclays, exiting entirely with an estimated $158K sold.
- 25 institutional investors held Benitec Biopharma (BNTC) as of Q3 2022, up from 21 in Q2 2022.
- Funds reported $5.92M of Benitec Biopharma stock for Q3 2022, up 281% quarter-over-quarter.
- 10 funds opened new Benitec Biopharma positions in Q3 2022 and 6 closed out, a net change of +4 holders.
- The largest Benitec Biopharma buyer in Q3 2022 was Franklin Resources, an estimated $7.47M added.
- The largest Benitec Biopharma seller in Q3 2022 was Barclays, an estimated $158K sold.
Based on aggregated 13F filings for Q3 2022.